Loratadine Dosing in End-Stage Renal Failure
In patients with end-stage renal disease (ESRF) on hemodialysis or peritoneal dialysis, loratadine should be dosed at 10 mg every other day (or 5 mg daily), as the active metabolite descarboethoxyloratadine accumulates significantly in renal failure despite minimal changes in parent drug clearance.
Rationale for Dose Adjustment
The FDA labeling explicitly states that consumers with kidney disease should "ask a doctor" before using standard doses 1. This caution is warranted based on pharmacokinetic data showing that while loratadine itself is not significantly affected by renal dysfunction, its primary active metabolite descarboethoxyloratadine demonstrates substantially increased exposure in patients with severe renal insufficiency 2.
Key Pharmacokinetic Findings
A dedicated renal impairment study demonstrated that:
- Parent drug (loratadine): No significant changes in half-life (8.7 vs 7.6 vs 8.6 hours in normal, renal failure, and hemodialysis patients respectively), clearance, or volume of distribution 2
- Active metabolite (descarboethoxyloratadine): AUC increased more than 2-fold in chronic renal failure patients (469.5 ng·hr/mL) compared to normal renal function (212.4 ng·hr/mL) 2
- Hemodialysis effect: Negligible removal (<1% augmentation of endogenous clearance), making supplemental dosing after dialysis unnecessary 2
Practical Dosing Recommendations
For hemodialysis patients:
- Start with 10 mg every other day
- Alternatively, use 5 mg daily if more consistent daily dosing is preferred
- No supplemental dose needed post-dialysis given minimal dialytic clearance
For peritoneal dialysis patients:
- Apply the same dosing as hemodialysis patients (10 mg every other day or 5 mg daily)
- Peritoneal dialysis removes even less drug than hemodialysis, so no additional adjustments needed 3
Clinical Context and Monitoring
The standard adult dose is 10 mg once daily 1. The dose reduction in ESRF is driven entirely by metabolite accumulation rather than parent drug changes. While loratadine is generally well-tolerated, the accumulated active metabolite could theoretically increase the risk of:
- Sedation (though loratadine is considered non-sedating at standard doses)
- QT prolongation (rare but documented with antihistamines)
- Anticholinergic effects
Important caveat: One study examining desloratadine (a related second-generation antihistamine) for uremic pruritus used 5 mg three times weekly in hemodialysis patients with good tolerability 4. This suggests that even conservative dosing is safe, though this was desloratadine rather than loratadine specifically.
Comparison with Other Antihistamines in ESRF
The British Association of Dermatologists guidelines note that cetirizine 10 mg daily was ineffective for uremic pruritus and that long-term sedating antihistamines should be avoided in this population due to dementia risk 5. This reinforces the importance of using appropriate doses of non-sedating antihistamines like loratadine when indicated.
Bottom line: Reduce the dose by 50% (either 10 mg every other day or 5 mg daily) in all ESRF patients regardless of dialysis modality, monitor for efficacy and any sedation, and do not give supplemental doses after hemodialysis sessions.